…
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -109.00M | -89.30M | -111.57M | -166.01M | -174.52M |
| Net income | -109.00M | -89.30M | -111.57M | -169.58M | -175.46M |
| Selling general administrative | 33.87M | 28.95M | 30.05M | 37.36M | 41.32M |
| Selling and marketing expenses | - | - | 1.37M | - | - |
| Gross profit | 9.77M | 8.33M | 15.45M | 2.50M | - |
| Reconciled depreciation | 1.15M | 1.25M | 1.37M | 1.17M | 0.49M |
| Ebit | -108.93M | -89.20M | -106.57M | -162.45M | -173.27M |
| Ebitda | -107.79M | -87.95M | -105.20M | -125.80M | -173.09M |
| Depreciation and amortization | 1.15M | 1.25M | 1.37M | 36.65M | 0.17M |
| Operating income | -110.50M | -91.46M | -72.44M | -162.45M | -173.27M |
| Other operating expenses | 120.27M | 99.79M | 87.89M | 128.53M | 173.27M |
| Interest expense | 0.06M | 0.10M | 5.00M | 3.80M | 1.43M |
| Interest income | 9.22M | 6.94M | 1.85M | 0.25M | 0.17M |
| Net interest income | 9.16M | 6.84M | -3.74M | -3.55M | -1.26M |
| Income tax expense | - | -89.30M | 1.20M | 3.57M | 0.94M |
| Total revenue | 9.77M | 8.33M | 15.45M | 2.50M | 0.00M |
| Total operating expenses | 120.27M | 99.79M | 87.89M | 128.53M | 173.27M |
| Cost of revenue | 1.15M | 1.25M | 1.37M | - | - |
| Total other income expense net | 1.50M | 2.16M | -39.13M | -3.57M | -1.26M |
| Net income from continuing ops | -109.00M | -89.30M | -214.38M | -166.01M | -174.52M |
| Net income applicable to common shares | - | - | - | - | -174.52M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 343.32M | 160.36M | 266.99M | 126.28M | 213.96M |
| Other current assets | 4.88M | 3.09M | 4.80M | 8.54M | 10.50M |
| Total liab | 96.38M | 88.84M | 192.06M | 125.33M | 118.57M |
| Total stockholder equity | 246.94M | 71.53M | 74.94M | 0.95M | 95.38M |
| Other current liab | 20.28M | 10.98M | 10.64M | 16.77M | 29.98M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -711.30M | -602.30M | -513.01M | -401.44M | -235.65M |
| Other liab | - | - | - | 4.13M | 3.73M |
| Other assets | - | - | - | 3.95M | 3.74M |
| Cash | 319.77M | 139.04M | 144.39M | 87.88M | 149.10M |
| Total current liabilities | 26.55M | 26.23M | 36.76M | 62.79M | 51.75M |
| Current deferred revenue | - | 9.77M | 18.11M | 33.56M | - |
| Net debt | -301.60M | -75.86M | -83.28M | -27.95M | -86.01M |
| Short term debt | - | 1.88M | 1.65M | 1.52M | - |
| Short long term debt total | 18.17M | 63.18M | 61.11M | 59.93M | 63.09M |
| Other stockholder equity | 958.43M | 677.86M | 587.94M | 402.39M | 331.03M |
| Property plant equipment | - | - | - | - | 50.61M |
| Total current assets | 324.65M | 142.13M | 149.19M | 96.42M | 159.60M |
| Net tangible assets | - | - | - | - | 95.38M |
| Long term debt | 50.11M | 43.94M | 40.51M | 37.97M | 37.19M |
| Accounts payable | 6.28M | 3.59M | 6.37M | 10.95M | 21.76M |
| Accumulated other comprehensive income | -0.19M | -4.03M | 0.00M | - | - |
| Non currrent assets other | 0.18M | 2.37M | 0.98M | 3.95M | 3.74M |
| Non current assets total | 18.67M | 18.23M | 117.81M | 29.86M | 54.35M |
| Capital lease obligations | 20.04M | 19.24M | 20.60M | 21.96M | 25.90M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.36M | -9.71M | -24.93M | -21.55M |
| Change to liabilities | - | - | - | 33.56M | 14.49M |
| Total cashflows from investing activities | -0.60M | -0.36M | -7.35M | -24.93M | -21.55M |
| Net borrowings | 9.24M | 0.00M | -3.45M | - | 39.96M |
| Total cash from financing activities | 274.59M | 76.68M | 136.39M | 52.10M | 39.08M |
| Change to operating activities | - | - | - | -7.24M | 14.17M |
| Net income | -109.00M | -89.30M | -111.57M | -166.01M | -174.52M |
| Change in cash | 180.90M | -4.90M | 56.02M | -61.22M | -99.51M |
| Begin period cash flow | 141.64M | 146.54M | 90.52M | 151.74M | 251.25M |
| End period cash flow | 322.53M | 141.64M | 146.54M | 90.52M | 151.74M |
| Total cash from operating activities | -93.09M | -81.22M | -73.02M | -88.39M | -117.04M |
| Issuance of capital stock | 264.31M | 76.78M | 182.82M | 53.24M | 0.00M |
| Depreciation | 1.15M | 1.25M | 1.37M | 1.17M | 0.49M |
| Other cashflows from investing activities | 0.13M | 0.01M | -3.48M | -0.06M | -0.06M |
| Other cashflows from financing activities | -0.34M | -0.10M | -0.95M | -1.15M | 39.08M |
| Change to netincome | - | - | - | 57.93M | 28.32M |
| Capital expenditures | 0.74M | 0.37M | 7.37M | 24.87M | 21.55M |
| Change in working capital | -5.37M | -12.47M | -18.01M | 18.52M | 28.67M |
| Stock based compensation | 13.30M | 13.10M | 7.91M | 18.04M | 18.18M |
| Other non cash items | 6.83M | 6.19M | 47.28M | 39.89M | 10.14M |
| Free cash flow | -93.83M | -81.60M | -80.39M | -113.26M | -138.60M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies Inc |
0.09 2.25% |
4.09 | - | - | 300.59 | 4.22 | 225.23 | -0.61 |
| NVO Novo Nordisk A/S |
-0.64 1.57% |
40.06 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
8.09 1.51% |
542.29 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
2.85 0.30% |
960.62 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
| Name | Title | Year Born |
|---|---|---|
| Mr. R. A. Session II | Founder, Pres, CEO & Director | 1979 |
| Mr. Kamran Alam CPA, M.B.A. | Chief Financial Officer | 1978 |
| Dr. Suyash Prasad FFPM, M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M | Chief Medical Officer and Head of R&D | 1970 |
| Mr. Frederick Porter Ph.D. | Chief Technical Officer | NA |
| Mr. Jim Rouse | Chief Information Officer | NA |
| Ms. Tracy M. Porter | Chief People Officer | NA |
| Ms. Emily McGinnis M.P.H. | Chief Patient Officer & Head of Gov. Affairs | NA |
| Ms. Mishima Gerhart | Chief Regulatory Officer & Head of Quality | NA |
| Mr. Sean McAuliffe | Chief Commercial Officer | NA |
| Mr. Greg Gara | Sr. VP of Manufacturing | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.